Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 8, 2023
Reporting Period: First Quarter ended March 31, 2023
This filing serves as a notification that the Company issued a press release (Exhibit 99.1) announcing its results of operations and financial condition for the first quarter of 2023. Additionally, an updated investor presentation (Exhibit 99.2) was released for use in investor meetings.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The provided text does not contain specific numerical values for revenue, net income, cash flow, operating margins, debt levels, or liquidity ratios. These figures are contained within the referenced press release (Exhibit 99.1) and investor presentation (Exhibit 99.2), which are incorporated by reference but not detailed in the body of this 8-K filing.
Material Changes
The filing does not explicitly detail material changes in financial performance compared to the prior period. It solely confirms the issuance of the Q1 2023 results and an updated investor presentation.
Guidance, Outlook, and Risks
Disclosure Channels: The Company utilizes SEC filings, its investor relations website (https://ir.recursion.com/), press releases, public conference calls, webcasts, and social media to communicate material information.
Legal Disclaimer: The information furnished under Item 2.02 and Item 7.01, including the exhibits, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2023 financial results, including revenue, net loss, and cash position.
- Examine Exhibit 99.2 (Investor Presentation) for updated strategic outlook, pipeline progress, and management commentary.
- Verify the Company's cash runway and burn rate, as these are critical for a pre-revenue biotechnology firm but are not listed in this summary text.
- Monitor the investor relations website for any subsequent updates to disclosure channels or material information.